Market Research Reports and Industry Reports

Targeted Therapies in Asthma [2017]: Bulletin #2

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS



This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the severe asthma treatment landscape. Topics covered include; Novartis announcing the results from the Still Fighting for Breath survey which demonstrates that despite the widespread availability of oral and inhaled treatments, asthma still places a huge burden on the personal and professional lives of those living with the disease in Europe. Critically, data from the surveys shows that 94 percent of severe allergic asthma patients were unable to fully control their disease; AstraZeneca presenting data from the Phase III ZONDA trial, which demonstrated that adding benralizumab (a fully humanised anti-interleukin [IL]-5 monoclonal antibody) to standard of care allowed patients dependent on oral corticosteroids (OCS) to significantly reduce or discontinue steroids while maintaining asthma control. The trial achieved its primary efficacy endpoint, demonstrating a statistically significant and clinically relevant reduction in daily maintenance OCS use with two benralizumab dosing regimens compared with placebo, and also demonstrated significant outcomes for secondary endpoints; Teva presenting new data on Cinqair/Cinqaero (reslizumab), an anti-IL-5 mAb approved in the US and Europe as add-on maintenance treatment for patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype. New data comes from a post-hoc pooled analysis of the Phase III BREATH study, and studies on the efficacy of reslizumab in patients eligible for Xolair (omalizumab; Roche/Novartis).





Business Questions:

Were KOLs surprised by the data from the Still Fighting for Breath survey, and do they believe any lessons can be learned?

Could differences in access to therapy in each European country that took part in the Still Fighting for Breath survey make data interpretation very challenging, or can the findings be taken at face value?

Do KOLs believe that the data from the Still Fighting for Breath survey will have any impact on how severe asthma is treated, and do they believe the GINA (The Global
Initiative for Asthma) guidelines need to be modified?


Is more head to head data needed for biologic therapies that better ways of controlling exacerbations can be found, or is it simply a case of better education and better use of current treatments?

What was most impressive about the data from the Phase III ZONDA study for benralizumab; changes in steroid usage, hospitalisation rates, exacerbation rates, or all of the above?

Will benralizumabs mechanism of action, steroid-sparing ability, and dosing schedule could help drive clinical differentiation?

How will benralizumab be used in the treatment of severe eosinophilic asthma, and what challenges face AstraZeneca in terms of differentiating benralizumab from other anti-IL-5 mAbs?

Are formulation problems preventing reslizumab from capturing significant market share in the US, or are other forces at play?

What does the future hold for the use of biologics in the treatment of severe asthma?

Targeted Therapies in Asthma [2017]: Bulletin #2

This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the severe asthma treatment landscape.

USD 1045View Report

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as

USD 4995View Report

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as

USD 4995View Report

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Market Research Report

Based on the Autologous Stem Cell and Non-Stem Cell Based Therapies industrial chain, this report mainly elaborate the definition, types, applications and major players of Autologous Stem Cell and Non-Stem

USD 2960View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Jul 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
pendik escort tuzla escort antalya escort bayan kartal escort
instagram takipci hilesi
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop